Oxygenta Pharmaceutical (524636) Q4 24/25 earnings summary

Executive summary

• Audited financial results for Q4 and full year ended March 31, 2025, were approved by the board and reviewed by the audit committee.

• The company shifted its corporate office within Hyderabad effective May 30, 2025.

Financial highlights

• Q4 FY25 revenue from operations was ₹4,946.66 lakhs, up from ₹1,055.24 lakhs in Q4 FY24.

• Total income for FY25 was ₹11,060.77 lakhs, compared to ₹3,968.45 lakhs in FY24.

• Net loss for FY25 stood at ₹1,029.83 lakhs, versus a loss of ₹347.93 lakhs in FY24.

• Q4 FY25 net loss was ₹215.29 lakhs, compared to a net profit of ₹801.58 lakhs in Q4 FY24.

• Basic and diluted EPS for FY25 was (₹2.86), compared to (₹1.04) in FY24.

Outlook and guidance

• The company is prioritizing compliance and transparency, focusing on accurate MSME creditor identification and bill-to-bill adjustment processes.